Enliven Therapeutics ELVN Current ratio

Current ratio at other companies

Bristol-Myers SquibbBMY

1.5×+0.3×

PfizerPFE

1.2×0.0×

ImmunityBio, Inc.IBRX

6.7×+4.4×

Iovance Biotherapeutics, Inc.IOVA

4.3×+1.1×

Syndax PharmaceuticalsSNDX

5.5×-0.3×

CTO

Citius Oncology, Inc.CTOR

0.5×+0.1×

FAQ

What is Enliven Therapeutics's current ratio?

Enliven Therapeutics (ELVN) reported current ratio of 40.3× in Q1 2026.

How has Enliven Therapeutics's current ratio changed year-over-year?

Enliven Therapeutics's current ratio increased by 91.4% year-over-year, from 21.1× to 40.3×.

What is the long-term trend for Enliven Therapeutics's current ratio?

Over 5 years (2020 to 2025), Enliven Therapeutics's current ratio has grown at a 14.6% compound annual growth rate (CAGR), from 14.5× to 28.7×.

What does current ratio mean?

Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.